Monitoring complement biomarkers in C3 glomerulopathy patients with factor H or FHR gene mutations before and after treatment with eculizumab or ravulizumab

Vanderliek K, Afonso S, Loeschmann I, Krebs C, Wiech T, Skerka C, Zipfel P, Wiesener M (2022)

Publication Type: Conference contribution

Publication year: 2022

Journal

Molecular Immunology Elsevier

Publisher: PERGAMON-ELSEVIER SCIENCE LTD

City/Town: OXFORD

Pages Range: 201-201

Conference Proceedings Title: MOLECULAR IMMUNOLOGY

Authors with CRIS profile

Michael Wiesener Professur für Innere Medizin (Nephrologie)

Involved external institutions

Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie (Hans-Knöll-Institut (HKI)) / Leibniz Institute for Natural Product Research and Infection Biology DE Germany (DE) Universitätsklinikum Hamburg-Eppendorf (UKE) DE Germany (DE)

How to cite

APA:

Vanderliek, K., Afonso, S., Loeschmann, I., Krebs, C., Wiech, T., Skerka, C.,... Wiesener, M. (2022). Monitoring complement biomarkers in C3 glomerulopathy patients with factor H or FHR gene mutations before and after treatment with eculizumab or ravulizumab. In MOLECULAR IMMUNOLOGY (pp. 201-201). OXFORD: PERGAMON-ELSEVIER SCIENCE LTD.

MLA:

Vanderliek, Kim, et al. "Monitoring complement biomarkers in C3 glomerulopathy patients with factor H or FHR gene mutations before and after treatment with eculizumab or ravulizumab." Proceedings of the MOLECULAR IMMUNOLOGY OXFORD: PERGAMON-ELSEVIER SCIENCE LTD, 2022. 201-201.

BibTeX: Download